Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 260 participants.

Also called NCT02948998

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 260 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02948998
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02948998. Randomized; no masking; primary purpose treatment. Start 2018-05-14 (anticipated); primary completion 2019-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy
Condition
Hypertrophic Cardiomyopathy
Condition
Fibrosis
Intervention (Drug)
Spironolactone
Lead sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (class: other)
Collaborator
Ruijin Hospital (class: other)
Collaborator
RenJi Hospital (class: other)
Collaborator
Shanghai Jiao Tong University Affiliated Sixth People's Hospital (class: other)

Record details

Record id
cardio:ct-nct02948998
Content hash
0ecf6bfbbccf9b7fc9feb45407dd891fb23cc68a1ba01f9dc764b5c597095866